From this [1] 2017 report: > pharmaceutical and biotechnology sales revenue increased from $534 billion to $775 billion between 2006 and 2015 > worldwide comp

From this [1] 2017 report: > pharmaceutical and biotechnology sales revenue increased from $534 billion to $775 billion between 2006 and 2015 > worldwide company-reported R&D spending, most of which went to drug development (rather than research) ... $89 billion in 2015 dollars > During the same period, federal spending, which funded a greater amount of basic research relative to industry, remained stable at around $28 billion So only ~11% of total revenue was being reinvested, mostly into drug development. And basic research was funded largely by federal spending. [1] https://www.gao.gov/products/gao-18-40 https://www.gao.gov/products/gao-18-40